Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 206, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112702
Keywords
COVID-19; SARS-CoV-2 3C-like protease; N-substituted isatin compounds; In vitro assay; Structure-activity relationship
Categories
Funding
- National Natural Science Foundation of China [21633001,21877003]
- Ministry of Science and Technology of China [2016YFA0502303]
Ask authors/readers for more resources
SARS-CoV-2 3C like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC50's of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs. (C) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available